Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prostate Health Index (Phi) and Prostate Cancer Antigen 3 (PCA3) significantly improve prostate cancer detection at initial biopsy in a total PSA range of 2-10 ng/ml.
Ferro M, Bruzzese D, Perdonà S, Marino A, Mazzarella C, Perruolo G, D'Esposito V, Cosimato V, Buonerba C, Di Lorenzo G, Musi G, De Cobelli O, Chun FK, Terracciano D. Ferro M, et al. Among authors: cosimato v. PLoS One. 2013 Jul 4;8(7):e67687. doi: 10.1371/journal.pone.0067687. Print 2013. PLoS One. 2013. PMID: 23861782 Free PMC article.
Biomarkers in localized prostate cancer.
Ferro M, Buonerba C, Terracciano D, Lucarelli G, Cosimato V, Bottero D, Deliu VM, Ditonno P, Perdonà S, Autorino R, Coman I, De Placido S, Di Lorenzo G, De Cobelli O. Ferro M, et al. Among authors: cosimato v. Future Oncol. 2016 Feb;12(3):399-411. doi: 10.2217/fon.15.318. Epub 2016 Jan 15. Future Oncol. 2016. PMID: 26768791 Free PMC article. Review.
Improving the prediction of pathologic outcomes in patients undergoing radical prostatectomy: the value of prostate cancer antigen 3 (PCA3), prostate health index (phi) and sarcosine.
Ferro M, Lucarelli G, Bruzzese D, Perdonà S, Mazzarella C, Perruolo G, Marino A, Cosimato V, Giorgio E, Tagliamonte V, Bottero D, De Cobelli O, Terracciano D. Ferro M, et al. Among authors: cosimato v. Anticancer Res. 2015 Feb;35(2):1017-23. Anticancer Res. 2015. PMID: 25667489 Free article.
Incidence of fatigue and low-dose corticosteroid use in prostate cancer patients receiving systemic treatment: a meta-analysis of randomized controlled trials.
Ferro M, Di Lorenzo G, de Cobelli O, Bruzzese D, Pignataro P, Borghesi M, Musi G, Vartolomei MD, Cosimato V, Serino A, Ieluzzi V, Terracciano D, Damiano R, Cantiello F, Mistretta FA, Muto M, Lucarelli G, De Placido P, Buonerba C. Ferro M, et al. Among authors: cosimato v. World J Urol. 2019 Jun;37(6):1049-1059. doi: 10.1007/s00345-018-2579-x. Epub 2018 Dec 5. World J Urol. 2019. PMID: 30519742
A risk-group classification model in patients with bladder cancer under neoadjuvant cisplatin-based combination chemotherapy.
Ferro M, Lucarelli G, de Cobelli O, Dolce P, Terracciano D, Musi G, Porreca A, Busetto GM, Del Giudice F, Soria F, Gontero P, Cantiello F, Damiano R, Crocerossa F, Abu Farhan AR, Autorino R, Vartolomei MD, Marchioni M, Mari A, Minervini A, Longo N, Celentano G, Chiancone F, Perdonà S, Del Prete P, Ditonno P, Battaglia M, Zamboni S, Antonelli A, Greco F, Russo GI, Hurle R, Crisan N, Manfredi M, Porpiglia F, Ribera D, De Placido P, Facchini S, Scafuri L, Verde A, Di Lorenzo G, Cosimato V, Luciano A, Caputo VF, Crocetto F, Buonerba C. Ferro M, et al. Among authors: cosimato v. Future Oncol. 2021 Oct;17(30):3987-3994. doi: 10.2217/fon-2020-1298. Epub 2021 Jul 19. Future Oncol. 2021. PMID: 34278815
13 results